Citations 1
Albumin In Situ Hybridization Can Be Positive in Adenocarcinomas and Other Tumors From Diverse Sites
Nasir, Aqsa , Lehrke, Heidi D., Mounajjed, Taofic, Said, Samar M. , Zhang, Lizhi , Yasir, Saba , Shah, Sejal , Chandan, Vishal S. , Smyrk, Thomas C. , Moreira, Roger K. , Froemming, Jennifer M. Boland, Hernandez, Loren P. Herrera , Wu, Tsung‐Teh, Graham, Rondell P. , Said, Samar, Shah, Sejal S, Boland Froemming, Jennifer M, Herrera Hernandez, Loren P, Graham, Rondell P , Froemming, Jennifer Boland
American Journal of Clinical Pathology | March 4, 2019 | Volume: 152 | Issue: 2 | Pages: 190-199
ABSTRACT Objectives Albumin messenger RNA (mRNA) expression is a marker of hepatocellular differentiation. Most published data are from review of tissue microarrays, and albumin in situ hybridization (ISH) expression across several tumor types is incompletely characterized. Methods Sections from 221 tumors were evaluated for albumin mRNA. Immunohistochemistry was used to confirm diagnoses. Albumin ISH was performed according to manufacturer-provided instructions. Fifty-nine cases were evaluated with both commercial ISH assays. Results Albumin mRNA was detected in all hepatocellular carcinomas (HCCs) and 81% of intrahepatic cholangiocarcinomas. Lung (20%), gallbladder (39%), hepatoid pancreatic (n = 1 of 1) adenocarcinoma, breast invasive ductal carcinoma (18%), yolk sac tumor (25%), and acinar cell carcinoma (29%) showed expression. Both assays were concordant in 93% of cases. Conclusions Albumin ISH was expressed in all HCCs studied. It was also positive in intrahepatic cholangiocarcinoma and patchy positive in gallbladder adenocarcinoma and a subset of other neoplasms, which can be a potential pitfall.